3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Sarcoma
4
Thyroid Cancer, Papillary
2
Salivary Gland Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Breast Neoplasms
2
Brain Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
25
Temozolomide
22
Vincristine
18
Irinotecan
18
Doxorubicin
13
Topotecan
10
Melphalan
10
Etoposide
10
Ifosfamide
8
Busulfan
8
cabozantinib
7
Magnetic Resonance Spectroscopy
7
Granulocyte Colony-Stimulating Factor
7
Filgrastim
6
regorafenib
5
fludarabine
5
X-Rays
5
Specimen Handling
5
Sirolimus
5
Radiotherapy
5
Gemcitabine
5
Drug Therapy
5
pegfilgrastim
4
palbociclib
4
liposomal doxorubicin
4
irinotecan sucrosofate
4
ganitumab
4
fludarabine phosphate
4
Trabectedin
4
Phantoms, Imaging
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Ewing
×
entrectinib
×
Sarcoma
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA